Common Contracts
2 similar Clinical Study Agreement contracts
CLINICAL STUDY AGREEMENT PROTOCOL: DAL-301 SITE: 18-106 DALCOR PHARMA UK LTD 07 - OCT- 2016 VERSION: 1 . 0 COUNTRY : CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL: DAL-301 CENTRUM: 18-106 DALCOR PHARMA UK LTD 07 - ŘÍJEN- 2016 VERZE: 1 . 0 ZEMĚ:...Clinical Study Agreement • October 11th, 2016
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), dated 07-OCT-2016 (the “Effective Date”), is entered into by and between the partiesMedpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA (“Medpace”),andFakultni nemocnice Brno, a clinical research site with its principal office and place of business at Jihlavska 20, 625 00 Brno, Czech Republic, company registration number: 65269705, tax identification number: CZ65269705 (“Institution”),and .Medpace, Institution, and Principal Investigator are sometimes collectively referred to herein as parties (the “Parties”). DalCor Pharma UK Ltd (“Sponsor”) is sponsoring a clinical study on the compound Dalcetrapib (the “Study Drug”), in accordance with Protocol No. DAL-301, titled “A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary
